Tubulis is a verified, high-potential clinical-stage biotechnology company specializing in 'antibody-drug conjugates' (ADCs) for cancer treatment. External verification confirms the company raised a massive €308M Series C in October 2025 (approx. $360M) and a €128M Series B2 in 2024, with total funding exceeding $500M and a strategic partnership with Bristol Myers Squibb. The project demonstrates exceptional Real-World Utility and Technical Innovation. However, the specific submission provided was of extremely low quality, containing factually incorrect claims such as 'everyone' audience reach, 'most people have used my product' (false for a clinical drug), and '0' team size. The score reflects the verifiable high value of the company (Unicorn status), heavily weighted by external evidence, while penalizing the submission's poor accuracy.
Ready to Compete for $150k+ in Prizes?
Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes
Score Breakdown
Project Details
Algorithm Insights
Recommendations to Increase Usefulness Score
Document User Growth
Provide specific metrics on user acquisition and retention rates
Showcase Revenue Model
Detail sustainable monetization strategy and current revenue streams
Expand Evidence Base
Include testimonials, case studies, and third-party validation
Technical Roadmap
Share development milestones and feature completion timeline